Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 07, 2012 12:45pm
253 Views
Post# 20459647

RE: Ready for Breakout? Whiplash ?

RE: Ready for Breakout? Whiplash ?

RE"Sometimes it takes a couple of weeks before boards can review proposals being presented to them."

 

[S] As BRD's NR's are compiled by those purloiners (T1's, T2's & T3's WDP's) we can expect to see an inflection point (aka gap up, re-rating) once the NEW buyers decide to take a position on a T3 with some major upside.

 

Many juniors will not have to production profile and exploration upside that BRD has. Meaning, going into new POG heights the streamers & ETF's (e.g. Franko, Royal, Sandstorm) appear to have the attention of a fickle (aka risk adverse) market. Thus in a high risk portfolio (triangle) , building a solid base is key; with juniors forming the 5% of a high risk junior.

 

In a breakout, NEW buyers ALWAYS overtake the sellers especially if the sellers decide that they have held on long enough. Tax loss selling may be a moot point as they have to wait 30 days before buying back their shares.

 

BWDIK? Today's market appears to be controlled by those with an inside edge with the exchanges. The trick is how to benefit from this (alleged) relationship.

 

Cheers

Stanley 

Bullboard Posts